Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells

AIDS

Volumn 22, Issue 10, 2008, Pages 1131-1135

  Archin, Nancy M ^a   Eron, Joseph J ^a   Palmer, Sarah ^b   Hartmann Duff, Anne ^a   Martinson, Jeffery A ^c   Wiegand, Ann ^b   Bandarenko, Nicholas ^a   Schmitz, John L ^a   Bosch, Ronald J ^d   Landay, Alan L ^c   Coffin, John M ^b   Margolis, David M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; HIV; Latency; Resting CD4+ T cells; Valproic acid

Indexed keywords

ANTIRETROVIRUS AGENT; VALPROATE SEMISODIUM; VIRUS RNA; ENZYME INHIBITOR; HISTONE DEACETYLASE; VALPROIC ACID;

ADD ON THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; PERSISTENT INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; CD4 CD8 RATIO; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HISTONE DEACETYLASES; HIV INFECTIONS; HIV-1; HUMANS; MALE; RNA, VIRAL; VALPROIC ACID; VIREMIA;

EID: 50949131800     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282fd6df4     Document Type: Article

References (31)

1. Gulick RM, MellorsJW, Havlir D, EronJJ, GonzalezC, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
2. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-843.
3. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368:451-458.
4. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
5. Di MascioM, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, et al. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J Virol 2003; 77:2271-2275.
6. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-1613.
7. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
8. WongJK, HezarehM, Gunthard HF, HavlirDV, IgnacioCC,Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-1295.
9. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
10. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997; 94:13193-13197.
11. Margolis DM, Somasundaran M, Green MR. Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol 1994; 68:905-910.
12. Romerio F, Gabriel M, Margolis DM. Repression of HIV-1 through the novel cooperation of the human factors YY1 and LSF. J Virol 1997; 71:9375-9382.
13. Coull J, Romerio F, Sun JM, Volker JM, Galvin KM, Davie JR, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type-1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000; 74:6790-6799.
14. Imai K, Okamoto T. Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem 2006; 281:12495-12505.
15. Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 2007; 26:412-423.
16. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 2006; 25:139-149.
17. He G, Margolis DM. Counter-regulation of chromatin acetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 by the HIV-1 activator tat and the HIV-1 repressor YY1. Mol Cell Biol 2002; 22:2965-2973.
18. Ylisastigui L, Coull JJ, Rucker V, Bosch RJ, Brodie SJ, Corey L, et al. Polyamides reveal a role for repression in viral latency within HIV-infected donors' resting CD4R T cells. J Infect Dis 2004; 190:1429-1437.
19. Ylisastigui L, Archin N, Lehrman G, Bosch RJ, Margolis DM. Coaxing human immunodeficiency virus type 1 from resting CD4R T cells: can the reservoir of HIV be purged? AIDS 2004; 18:1101-1108.
20. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 2002; 76:11091-11103.
21. Lehrman G, HogueIB, Palmer S, Jennings C, SpinaCA, Wiegand A, et al. Depletion of latent HIV infection in vivo. Lancet 2005; 36:549-555.
22. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000; 14: 761-770.
23. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8R T cells. Blood 2006; 107: 4781-4789.
24. Nomura LE, Emu B, Hoh R, Haaland P, Deeks SG, Martin JN, et al. IL-2 production correlates with effector cell differentiation in HIV-specific CD8R T cells. AIDS Res Ther 2006; 3: 18.
25. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-4536.
26. Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-829.
27. Gunthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001; 183:1318-1327.
28. Siliciano JD, Lai J, CallenderM, Pitt E, Zhang H, Margolick JB, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833-836.
29. Jones LE, Perelson AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 45:483-493.
30. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84-90.
31. Archin N, Espeseth A, Duff A, Cheema M, Parker D, Hazuda D, et al. Expression of Latent HIV induced by a selective class I HDAC inhibitor. In: Abstract of the 14th Annual Conference on Retroviruses and Opportunistic Infections 2007; Los Angeles, California [abstract 501].